Perspective Therapeutics to Participate in Upcoming December Conferences
Rhea-AI Summary
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in two investor conferences in early December 2025.
Events: Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 2, 2025 at 1:00–1:25 p.m. ET in New York, and Evercore 8th Annual Healthcare Conference fireside chat on Dec 3, 2025 at 3:00–3:20 p.m. ET in Miami. Management will also be available for one-on-one investor meetings.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CATX declined 7.83%, reflecting a notable negative market reaction. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $150M at that time.
Data tracked by StockTitan Argus on the day of publication.
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:
Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside Chat
Date: Tuesday, December 2, 2025
Time: 1:00 - 1:25 p.m. ET
Location: New York, NY
Evercore 8th Annual Healthcare Conference – Fireside Chat
Date: Wednesday, December 3, 2025
Time: 3:00 - 3:20 p.m. ET
Location: Miami, FL
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) present at the Piper Sandler conference?
What time is Perspective Therapeutics (CATX) scheduled at the Evercore Healthcare Conference?
Will Perspective Therapeutics (CATX) meet investors one-on-one at the December 2025 conferences?
Where can investors attend Perspective Therapeutics (CATX) conference events in December 2025?
Which executives from Perspective Therapeutics (CATX) will appear at the December 2025 conferences?
Are the fireside chat times for Perspective Therapeutics (CATX) given in Eastern Time?
